Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
67 hedge funds and large institutions have $229M invested in Bellicum Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 16 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 15
55% more capital invested
Capital invested by funds: $148M → $229M (+$80.8M)
14% less funds holding
Funds holding: 78 → 67 (-11)
35% less call options, than puts
Call options by funds: $346K | Put options by funds: $532K
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.9M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.62M |
| 3 |
First Eagle Investment Management
New York
|
+$2.96M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.91M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.81M |
| 2 |
Millennium Management
New York
|
-$2.58M |
| 3 |
JP Morgan Chase
New York
|
-$921K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$766K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$720K |
BLCM Hedge Fund Activity: Q2 2016 in Review
67 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2016, worth a combined $229M — up 55% from $148M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BLCM and 6 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 33 added.
The largest buyer was Fidelity Investments, adding an estimated $12.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.81M sold.
- 67 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2016, down from 78 in Q1 2016.
- Funds reported $229M of Bellicum Pharmaceuticals, Inc. stock for Q2 2016, up 55% quarter-over-quarter.
- 6 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2016 and 16 closed out, a net change of -10 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2016 was Fidelity Investments, an estimated $12.9M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2016 was Cormorant Asset Management, an estimated $2.81M sold.
Based on aggregated 13F filings for Q2 2016.